RVMD vs. EXEL, PCVX, IBRX, HALO, CRSP, KRYS, IMVT, IOVA, RGEN, and QGEN
Should you be buying Revolution Medicines stock or one of its competitors? The main competitors of Revolution Medicines include Exelixis (EXEL), Vaxcyte (PCVX), ImmunityBio (IBRX), Halozyme Therapeutics (HALO), CRISPR Therapeutics (CRSP), Krystal Biotech (KRYS), Immunovant (IMVT), Iovance Biotherapeutics (IOVA), Repligen (RGEN), and Qiagen (QGEN). These companies are all part of the "biological products, except diagnostic" industry.
Exelixis (NASDAQ:EXEL) and Revolution Medicines (NASDAQ:RVMD) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, community ranking, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.
Exelixis has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Comparatively, Revolution Medicines has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500.
Exelixis has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.
In the previous week, Revolution Medicines had 19 more articles in the media than Exelixis. MarketBeat recorded 31 mentions for Revolution Medicines and 12 mentions for Exelixis. Revolution Medicines' average media sentiment score of 0.65 beat Exelixis' score of 0.59 indicating that Exelixis is being referred to more favorably in the media.
Exelixis received 512 more outperform votes than Revolution Medicines when rated by MarketBeat users. However, 69.15% of users gave Revolution Medicines an outperform vote while only 68.12% of users gave Exelixis an outperform vote.
85.3% of Exelixis shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 2.9% of Exelixis shares are owned by insiders. Comparatively, 8.5% of Revolution Medicines shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Exelixis has a net margin of 11.10% compared to Exelixis' net margin of 0.00%. Revolution Medicines' return on equity of 8.85% beat Exelixis' return on equity.
Exelixis currently has a consensus target price of $26.13, suggesting a potential upside of 23.70%. Revolution Medicines has a consensus target price of $43.20, suggesting a potential upside of 9.45%. Given Revolution Medicines' higher possible upside, equities research analysts clearly believe Exelixis is more favorable than Revolution Medicines.
Summary
Exelixis beats Revolution Medicines on 11 of the 19 factors compared between the two stocks.
Get Revolution Medicines News Delivered to You Automatically
Sign up to receive the latest news and ratings for RVMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RVMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Revolution Medicines Competitors List
Related Companies and Tools
